Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Thiazolidinediones as potential therapeutic agents in atopic eczema.

Palomba LA, Ferrari Bardile C, Emanuele E.

Med Hypotheses. 2007;68(4):921-2. Epub 2006 Nov 13. No abstract available.

PMID:
17097827
2.

Gene (mRNA) expression in canine atopic dermatitis: microarray analysis.

Merryman-Simpson AE, Wood SH, Fretwell N, Jones PG, McLaren WM, McEwan NA, Clements DN, Carter SD, Ollier WE, Nuttall T.

Vet Dermatol. 2008 Apr;19(2):59-66. doi: 10.1111/j.1365-3164.2008.00653.x.

PMID:
18336422
3.
4.

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.

Grant PJ.

Heart. 2009 Feb;95(4):332; author reply 332. No abstract available.

PMID:
19176568
5.

The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.

Itakura H, Abbasi F, Lamendola C, Basina M, Reaven G.

Diabetes Obes Metab. 2008 Aug;10(8):685-7. doi: 10.1111/j.1463-1326.2008.00888.x. Epub 2008 May 12. No abstract available.

PMID:
18476981
6.

Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.

Charbonnel B.

Int J Clin Pract Suppl. 2007 Jun;(153):1-2. Review. No abstract available. Erratum in: Int J Clin Pract Suppl. 2007 Oct;61(10):1776.

PMID:
17594387
7.

Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes.

Kahn SE, Zinman B.

Diabetes Care. 2007 Jun;30(6):1672-6. Epub 2007 Mar 10. No abstract available.

PMID:
17351271
8.

Possible role of nerve growth factor and interleukin-18 in pathogenesis of eczematous lesions of atopic dermatitis.

Shaker OG, El-Komy M, Tawfic SO, Zeidan N, Tomairek RH.

J Dermatol Sci. 2009 Feb;53(2):153-4. doi: 10.1016/j.jdermsci.2008.08.018. Epub 2008 Oct 15. No abstract available.

PMID:
18922682
9.

A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.

Lehmann DF, Lohray BB.

J Clin Pharmacol. 2008 Aug;48(8):999-1002. doi: 10.1177/0091270008319791. No abstract available.

PMID:
18650500
10.

[Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].

Madsbad S.

Ugeskr Laeger. 2007 Nov 19;169(47):4054-7. Review. Danish. No abstract available.

PMID:
18078659
11.

Triple oral therapy for type 2 diabetes.

Bell DS.

Diabetes Res Clin Pract. 2007 Dec;78(3):313-5. Epub 2007 Feb 22. No abstract available.

PMID:
17320237
12.

Pleiotropic effects of thiazolidinediones.

Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS.

Expert Opin Pharmacother. 2008 May;9(7):1087-108. doi: 10.1517/14656566.9.7.1087. Review.

PMID:
18422468
13.

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.

Singh S, Furberg CD.

Heart. 2009 Jan;95(1):1-3. doi: 10.1136/hrt.2008.155507. Epub 2008 Aug 27. No abstract available.

PMID:
18753156
14.
15.

Inhibitory effect of a potent and selective cytosolic phospholipase A2alpha inhibitor RSC-3388 on skin inflammation in mice.

Yamamoto M, Haruna T, Imura K, Hikita I, Furue Y, Higashino K, Gahara Y, Deguchi M, Yasui K, Arimura A.

Pharmacology. 2008;81(4):301-11. doi: 10.1159/000117816. Epub 2008 Feb 21.

PMID:
18287786
16.

[Is there a need of glitazones in the treatment of diabetes?].

Halse J.

Tidsskr Nor Laegeforen. 2007 Aug 23;127(16):2124; author reply 2124. Norwegian. No abstract available.

17.

Studies of diabetes, thiazolidinediones, and coronary heart disease.

Walker AM, McAfee AT, Koro C.

Pharmacoepidemiol Drug Saf. 2007 Dec;16(12):1313-4; author reply 1314-6. No abstract available.

PMID:
18041104
18.

Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.

Anstey A.

Br J Dermatol. 2009 Aug;161(2):219-20. doi: 10.1111/j.1365-2133.2009.09218.x. No abstract available.

PMID:
19664122
19.

Actos and Avandia in type 2 diabetes. Where do they fit?

Clark W.

Diabetes Self Manag. 2007 Jul-Aug;24(4):8, 11-3. No abstract available.

PMID:
17663078
20.

Bone metabolism in type 2 diabetes and role of thiazolidinediones.

Vestergaard P.

Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):125-31. doi: 10.1097/MED.0b013e328325d155. Review.

PMID:
19300092

Supplemental Content

Support Center